載入中
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
前收盤價
US$2.75
−US$0.03 · -1.08%
盤前
US$2.7212
−US$0.0288 · -1.05%
10月8日 上午8:16 ET
盤中時間採用ET。市場資料可能有所延遲。
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
日內區間
目前US$2.75
52週區間
目前US$2.75
盤中時間採用ET。市場資料可能有所延遲。
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
日內區間
目前US$2.75
52週區間
目前US$2.75
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 1.54億 USD | 7327.8萬 USD | 2767萬 USD | 2425萬 USD | 3839.6萬 USD |
| 銷售、一般及管理費用 | 1827.3萬 USD | 1761.2萬 USD | 1408.8萬 USD | 1227.6萬 USD | 1206.9萬 USD |
| 營業費用 | 1.72億 USD | 9089萬 USD | 4175.8萬 USD | 3652.6萬 USD | 5046.5萬 USD |
| 折舊和攤銷 | 35萬 USD | 31.8萬 USD | 31.1萬 USD | 31.8萬 USD | 32.6萬 USD |
| 營業利益 | −1.72億 USD | −9089萬 USD | −4175.8萬 USD | −3652.6萬 USD | −5046.5萬 USD |
| 淨利 | −1.66億 USD | −8060.4萬 USD | −3694.9萬 USD | −3535.5萬 USD | −5063.6萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$8.00
上漲空間 190.91%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2020年5月29日 | 1:12 | — | — |
已生效 2020年5月29日
1:12
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI842.86萬0.00%2.3兆 USD0.03%US$381.03-0.40%
iShares Russell 2000 ETFIWM485.88萬0.01%785.63億 USD0.19%US$277.7-1.29%
Fidelity Enhanced Small Cap ETFFESM271.45萬0.04%64.1億 USD0.28%US$45.22-1.14%
Vanguard Extended Market ETFVXF267.2萬0.00%954億 USD0.05%US$233.49-1.56%
iShares Russell 2000 Growth ETFIWO175.57萬0.01%142.49億 USD0.24%US$355.37-1.43%
Vanguard Russell 2000 ETFVTWO146.47萬0.01%180億 USD0.06%US$112.21-1.26%
Dimensional - US Small Cap ETFDFAS125.89萬0.00%336.6億 USD0.31%US$77.92-1.38%
iShares Biotechnology ETFIBB101.06萬0.01%104.01億 USD0.44%US$203.34+0.12%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMFidelity Enhanced Small Cap ETFFESMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
